Asset Details
Do you wish to reserve the book?
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Do you wish to request the book?
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
2019
Overview
In this open-label trial of first-line treatment for HIV-1 in Cameroon, a dolutegravir-based regimen was found to be noninferior to a low-dose efavirenz–based regimen as initial antiretroviral therapy. However, more weight gain and a higher incidence of obesity occurred in the dolutegravir group.
Publisher
Massachusetts Medical Society
Subject
